



Programme

08:00 - 09:00 REGISTRATION & COFFEE

09:00 - 09:05 WELCOME

Professor Mark Pritchard (Liverpool, UK)

09:05 – 10:30 MULTI DISCIPLINARY CHALLENGES IN CLINICAL PRACTICE

Chair: Professor Mark Pritchard (Liverpool, UK) and Dr John Ayuk (Birmingham, UK)

09:05 – 09:20 Management of pancreatic NETs in patients with genetic syndromes
Professor Rajesh Thakker (Oxford, UK)

09:20 – 09:35 SSAs in patients with NENs when Ki67>10%
Dr Elettra Merola (Rome, Italy)

09:35 – 09:50 Treatment options for patients with lung carcinoid
Dr Judith Cave (Southampton, UK)

09:50 – 10:05 Use of PRRT in patients with functional NETs
Dr Wouter Zandee (Groningen, The Netherlands)

10:05 – 10:20 Palliative and supportive care needs in patients with NENs
Dr Dina Pitsillides (Sheffield, UK)

10:20 – 10:30 Discussion

10:30 – 11:00 COFFEE, EXHIBITION AND POSTERS

11:00 – 12:15 DEBATE: This House believes that somatostatin analogues should be discontinued in patients with non functioning NETS after progression on such treatment prompts changing to alternative forms of systemic anti-tumour treatment or after PRRT

Chair: Professor John Newell-Price (Sheffield, UK)

11:00 – 11:30 Continuation VS Discontinuation (Un-progression and/or post PRRT)
Dr Olusola Faluyi (Liverpool, UK) & Dr Raj Srirajaskanthan (London, UK)

11:30 – 11:45 Challenges and uncertainties in managing patients with resected appendiceal NETs
Mr Hamish Clouston (Manchester, UK)

11:45 – 12:00 Liver resections in GEP-NEN – when and when not?
Mr Stuart Robinson (Newcastle, UK)

12:00 – 12:15 Updates in Clinical Trials from across the year
Dr Alan Anthony (Leeds, UK)

12:15 – 12:30 AGM – MEMBERS ONLY

12:15 – 13:50 LUNCH, EXHIBITION AND POSTERS

12:50 – 13:50 SATELLITE SYMPOSIA

14:00 – 14:45 MDT CHALLENGING THE EXPERTS

Chairs: Professor John Wadsley (Sheffield, UK) & Chrissie Thirlwell (Exeter, UK)

Oncologist
Professor Juan Valle (Manchester, UK)

Gastroenterologist
Dr Joe Geraghty (Manchester, UK)

Endocrinologist
Dr Daniel Morganstein (London, UK)

Surgeon
Professor Paul Skinner (Sheffield, UK)

Nuclear Medicine Physician
Dr Amarjot Chander (Manchester, UK)

Histopathologist
Dr Eve Fryer (Oxford, UK)

Consultant Radiologist
Dr Aisha Naseer (Oxford, UK)

Clinical Nurse Specialist
Sister Irene Wotherspoon (Glasgow, UK)

14:00 – 14:30 Case Presentations:

- 14:00-14:10 The clinical conundrum of treating well differentiated grade 3 neuroendocrine tumours
Melek Akay (London, UK)
- 14:10-14:20 Challenges in Diagnosis and Management
Zaira Rehman, (Birmingham, UK)
- 14:20-14:30 Small bowel obstruction following peptide receptor radionuclide therapy (PRRT) treatment for metastatic neuroendocrine tumour
Ayanna Gadsden-Jeffers (Southampton, UK)

14:45 – 15:30 TRANSLATIONAL MEDICINE

Chair: Dr Debashis Sarker (London, UK)

- 14:45-15:15 Multiomics characterisation of cancer and microenvironment of GEP-NETs
Anguraj Sadanandam (London, UK)
- 15:15-15:25 Epigenetic based biomarker discovery for extra-pulmonary neuroendocrine carcinoma
Melissa Frizziero (Manchester, UK)
- 15:25-15:30 Announcement of NCUK 2022 Research Award
Debashis Sarker (London, UK)

15:30 – 16:00 COFFEE, EXHIBITION & POSTERS

16:00 – 16:30 ORAL COMMUNICATIONS

Chairs: Dr Anjuraj Sadanandam (London, UK) & Dr Bahram Jafar-Mohammadi (Oxford, UK)

- 16:00 – 16:10 Urine 5-HIAA levels and Quality-of-Life in Neuroendocrine Neoplasia. Is there an association?
Rayhan Chaudhry (Basingstoke, UK)
- 16:10 – 16:20 Glucagonomas: diagnostic features and outcomes of first line treatment in a series of 18 patients
Alexander Branton (London, UK)

16:20 – 16:30 Outcomes in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours receiving PRRT early vs later
Matthew D Robinson (Manchester, UK)

16:30 – 17:00 PLENARY LECTURE/INTERNATIONAL SPEAKER'S LECTURE

Chair: Dr Mairéad McNamara (Manchester, UK)

Should patients with poorly differentiated extra pulmonary neuroendocrine carcinoma be treated differently based on primary tumour site?
Professor Emily Bergsland (San Francisco, USA)

17:00 – 17:20 PRIZE GIVING & CLOSING

Professor Mark Pritchard (Liverpool, UK)